The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial).
 
Leon Pappas
Stock and Other Ownership Interests - Lilly; Moderna Therapeutics
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Pashtoon Murtaza Kasi
Leadership - Precision Biosensors
Stock and Other Ownership Interests - Elicio Therapeutics
Consulting or Advisory Role - Bayer; BostonGene; BostonGene; Daiichi Sankyo/Astra Zeneca; Delcath Systems; Eisai; Elicio Therapeutics; Exact Sciences; Foundation Medicine; Guardant Health; Illumina; Ipsen (Inst); Lilly; MSD Oncology; Natera; NeoGenomics Laboratories; QED Therapeutics; SAGA Diagnostics; Seagen; SERVIER; Taiho Oncology; Taiho Pharmaceutical (Inst); Tempus
Research Funding - Advanced Accelerator Applications (Inst); Boston Scientific (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Manish A. Shah
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Oncolys BioPharma (Inst)
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; QED Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Ryan Bruce Corcoran
Leadership - Alterome Therapeutics; Sidewinder Therapeutics
Stock and Other Ownership Interests - Alterome Therapeutics; Avidity Biosciences; C4 Therapeutics; Cogent Biosciences; Erasca, Inc; Interline Therapeutics; Kinnate Biopharma; Nested Therapeutics; nRichDx; Remix Therapeutics; Revolution Medicines; Theonys
Consulting or Advisory Role - Abbvie; Array BioPharma; Asana Biosciences; C4 Therapeutics; Elicio Therapeutics; FOGPharma; Ipsen; Kinnate Biopharma; N-of-One; Natera; nRichDx; Remix Therapeutics; Revolution Medicines; Taiho Pharmaceutical
Research Funding - Lilly; Novartis; Pfizer
 
Luis A. Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Aparna Raj Parikh
Consulting or Advisory Role - Abbvie; Bayer; Biofidelity; Checkmate Pharmaceuticals; CVS; Delcath Systems; Foundation Medicine; Guardant Health; Illumina; Lilly; SAGA Diagnostics; Scarce; Seagen; Taiho Oncology; Takeda; UpToDate; Value Analytics Labs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); PMV Pharma; PureTech (Inst)
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; Parithera; Xact Robotics